Tel. +34 913303000 (Ext. 483269)
Tel. +34 913303000 (Ext. 482456)
The Cardiovascular Risk Laboratory of the Hospital Clínico San Carlos is a multidisciplinary research group consisting of biologists, nurses, physicians, engineers, and biostatisticians. Its main line of research is the identification of the mechanisms of development and progression of cardiovascular disease (CVD), as well as the study of new therapeutic approaches.
Our group has extensive experience in clinical and experimental research on the main cardiovascular risk factors, arterial hypertension, dyslipidaemia, obesity, and diabetes mellitus, as well as their main clinical consequences, arteriosclerosis, and heart failure. However, the incidence of CVD is not solely explained by the presence of these traditional risk factors, so our group has initiated the study of the relationship between gut microbiota (the set of microorganisms that live in our gut) and CVD, with the conviction that the composition of the intestinal microbiota and/or circulating microbial metabolites could be novel markers of cardiovascular risk, which could open the door to new therapeutic approaches (probiotics, prebiotics, or non-absorbable antimicrobial agents) for treatment and prevention, with the important impact that this would entail. Moreover, the gut microbiota can be highly influenced and modulated by environmental factors, such as air pollution, climate, nutrition, or physical exercise, and is therefore postulated as a linking mechanism between the exposome (the set of non-genetic factors to which a person is subjected from the moment of conception until death) and CVD. Thus, the study of the influence of the exposome may be central to future medicine as a strategy to prevent CVD.
Our group has belonged to the ISCIII research networks (RETICs) REDINSCOR (Heart Failure Research Network) and RIC (Cardiovascular Research Network) and, currently, to CIBERCV and CIBERDEM.
Dr. Dulcenombre Gómez Garre, PhD in Biological Sciences (UAM) with Extraordinary Prize and Biologist Specialist in Clinical Biochemistry, trained as a researcher at the Fundación Jiménez Díaz in Madrid.
Since 2007, she has been responsible for the Vascular Biology Laboratory at the Hospital Clínico San Carlos-IdISSC in Madrid and, more recently, for the Microbiota Laboratory.
In recent years, her work has focused on the study of the molecular basis of the inflammatory process associated with cardiovascular disease, mainly in arteriosclerosis and heart failure, as well as on the study of new therapeutic approaches.
He has published more than 65 papers in scientific journals, has presented more than 110 communications at national and international meetings and has supervised 8 doctoral theses. He has participated in 30 research projects and has received 17 research awards. His group has belonged to the REDINSCOR and RIC research networks and is currently part of the CIBERCV of the Instituto de Salud Carlos III.
She is a member of the Animal Experimentation Ethics Committee of the IdISSC. In addition, she is a reviewer for several scientific journals, for the National Agency for Evaluation and Prospective (ANEP) and for EITHealth’s Technological Innovation in Health projects.
